Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a

Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a

Item

http://www.wikidata.org/entity/Q34581660

Q34581660

about

Adjuvants: Classification, Modus Operandi, and Licensing Nasal vaccine innovation.A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers.Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses.Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination.Immunostimulative Activity of Low Molecular Weight Chitosans in RAW264.7 Macrophages.Starch microparticles as vaccine adjuvant.Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.Chitosan solution enhances the immunoadjuvant properties of GM-CSF.Molecular Weight-Dependent Immunostimulative Activity of Low Molecular Weight Chitosan via Regulating NF-κB and AP-1 Signaling Pathways in RAW264.7 Macrophages.Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials.Bioadhesive delivery systems for mucosal vaccine delivery.Chitosan-based delivery systems for mucosal vaccines.Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation.Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques.A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice.Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice.CriticalSorb™: enabling systemic delivery of macromolecules via the nasal route.Intranasal immunization with dry powder vaccines.An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery.Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.Adjuvant synergy: the effects of nasal coadministration of adjuvants.Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform.Diphtheria-neutralizing antibody levels in healthy adults from Rio de Janeiro, Brazil

P2860

Q26747586-E33F22F5-18FA-4F43-AE12-ACA69107A19B Q30395810-232B6108-60BD-401D-AA55-53C1F03E7488 Q30423922-1504B416-EF2E-442E-94B8-0AB3597C98F9 Q34033764-98069851-EC9B-4488-A399-34B0124F3347 Q34194667-42F0C7D1-7669-4BD4-9A4C-CE094246E0AD Q34206463-2BA93A85-D814-40F5-97AA-C89B60455E99 Q34293599-A8079EDC-DC40-4B22-9D30-70672BC749ED Q35839060-E012D988-EE8C-4C04-926E-30C3A5A63079 Q36226743-AC31B316-EEFA-4A2B-BB59-954CB5DE114D Q36316814-FB79C10D-EE3D-47C4-8EC0-D5BB95CB3CA6 Q36539669-CC120629-B023-46AE-8137-6FDBEFA0FB9C Q36868870-713AFE19-84E7-438A-B75E-AFD7311999BD Q37290929-12A12E84-598B-4EDB-A331-11F15DC26A5A Q37392189-A2E5C0CE-17D4-468F-8E8D-4A1B690D5C88 Q37805519-24209893-B80B-4FCF-AC68-ED0EC5585D37 Q38019583-836527E2-C68F-4CF4-905C-36F23E92386B Q38254989-C271E82E-9916-4097-8EE8-2B9B7223965C Q39045080-8F9E7AAA-7263-48E6-AE6C-ACCA25DEF38F Q40107672-7B64F4BB-C3CC-4B3C-A8E2-01D5E8DCC432 Q40309267-C1835DB9-F34A-463F-BDCF-A49830455E63 Q41196267-C567DF5C-3652-4D26-BDDC-AA3211D97904 Q47584590-60101BAD-30F0-481D-91CB-14CCD7493C79 Q47961163-B1C56F4B-A8A6-4CD3-8751-1A6D27056CDC Q51261778-830E2C0D-EFCB-4A94-923A-5C2BF1A08DF4 Q51996299-047F0527-931E-492A-A17A-6646EFF02B7B Q54474177-465732D0-6C01-4661-962C-665E04FDC539 Q58623696-660FAD75-AF6E-4B9F-84E6-9FDC4CED2352

P2860

Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a

Item

http://www.wikidata.org/entity/Q34581660

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu